Cabergoline for Galactorrhea
Cabergoline is the preferred dopamine agonist for treating galactorrhea associated with hyperprolactinemia, started at 0.25 mg twice weekly and titrated by 0.25 mg increments every 4 weeks based on prolactin levels, with a typical effective dose range of 0.25-3 mg/week. 1, 2
Initial Dosing Strategy
Start cabergoline at 0.25 mg twice weekly (0.5 mg/week total). This conservative starting dose minimizes side effects while initiating therapeutic effect 2. Do not increase the dose more rapidly than every 4 weeks—this allows adequate time to assess response at each dose level and prevents unnecessary escalation 2.
Dose titration: Increase by 0.25 mg twice weekly increments based on prolactin normalization. Most patients achieve control with 0.5-1.5 mg/week, though some require up to 3 mg/week, and occasionally up to 11 mg/week for resistant cases 1.
Why Cabergoline Over Bromocriptine
Cabergoline demonstrates superior efficacy: it normalizes prolactin in 83-95% of patients versus 59% with bromocriptine, and resolves galactorrhea in 73% versus 56% 1, 3. The drug has higher affinity for D2 dopamine receptors and causes fewer side effects (68% versus 78% adverse events), resulting in better compliance 1, 3. Only 3% discontinue cabergoline due to intolerance compared to 12% with bromocriptine 3.
Monitoring Protocol
Month 1: Check serum prolactin to guide dose adjustment. Continue monthly prolactin measurements until normalization is achieved 1.
Cardiac surveillance: Before starting treatment, perform cardiovascular evaluation and consider baseline echocardiography to assess for valvular disease 2. For patients requiring typical doses (1-2 mg/week), regular echocardiographic screening is likely not necessary. However, those on prolonged high-dose therapy (>2 mg/week for extended periods) should undergo periodic echocardiography to monitor for valvular abnormalities 1, 2.
Imaging: If a pituitary adenoma is present, repeat MRI at 1 year for microadenomas, or at 3 months for macroadenomas (or sooner if prolactin rises or new symptoms develop) 1.
Treatment Duration and Discontinuation
After maintaining normal prolactin levels for 6 months, consider discontinuing cabergoline with periodic prolactin monitoring 2. Evidence supports attempting withdrawal after at least 2 years of treatment in patients with normalized prolactin and no visible tumor remnant 1.
Recurrence risk: 26-69% of patients experience recurrence after withdrawal, most commonly within the first year. Recurrence is predicted by higher initial prolactin levels and larger tumor size 1.
Management of Intolerance or Resistance
For bromocriptine intolerance: Switch to cabergoline—84% of bromocriptine-intolerant patients achieve prolactin normalization with cabergoline 4.
For bromocriptine resistance: Switch to cabergoline—70-80% of bromocriptine-resistant patients respond to cabergoline 1, 4.
For cabergoline resistance (10% of patients): Consider transsphenoidal surgery for symptomatic patients who cannot tolerate or do not respond to dopamine agonists 1. For patients intolerant of oral bromocriptine, intravaginal administration may be attempted as an alternative 1.
Special Populations
Asymptomatic microprolactinomas: Treatment is not mandatory. For premenopausal women with amenorrhea from microadenomas who are not seeking pregnancy, oral contraceptives are a reasonable alternative to dopamine agonists—they are less expensive with fewer side effects, though amenorrhea cannot be used to monitor disease recurrence 1.
Pregnancy: Once pregnancy is achieved, cabergoline should typically be discontinued. Limited data exist on 199 pregnancies with 10 congenital abnormalities reported, though no consistent pattern emerged 5.
Common Pitfalls
- Dose escalation too rapid: Wait the full 4 weeks between increases to properly assess response 2
- Inadequate monitoring: Missing the 1-month prolactin check delays appropriate dose adjustment 1
- Premature discontinuation: Stopping before 6 months of normalized prolactin increases recurrence risk 2
- Overlooking cardiac risk: Failing to consider echocardiography in high-dose, long-term users 1, 2
- Treating asymptomatic microadenomas unnecessarily: These rarely grow and may not require dopamine agonist therapy 1